Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neurotoxicity Syndromes | 11 | 2023 | 290 | 4.400 |
Why?
|
Brain Neoplasms | 45 | 2024 | 8863 | 3.150 |
Why?
|
Glioblastoma | 27 | 2024 | 3481 | 3.150 |
Why?
|
Central Nervous System Neoplasms | 14 | 2023 | 895 | 2.810 |
Why?
|
Cranial Irradiation | 5 | 2017 | 401 | 2.060 |
Why?
|
Antineoplastic Agents, Alkylating | 7 | 2019 | 627 | 1.980 |
Why?
|
Lymphoma | 8 | 2023 | 1877 | 1.890 |
Why?
|
Glioma | 19 | 2022 | 3401 | 1.600 |
Why?
|
Immunotherapy, Adoptive | 11 | 2023 | 1270 | 1.560 |
Why?
|
Dacarbazine | 5 | 2016 | 566 | 1.430 |
Why?
|
Central Nervous System | 10 | 2023 | 1357 | 1.110 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 4 | 2021 | 1378 | 0.930 |
Why?
|
Radiation Injuries | 4 | 2019 | 1180 | 0.900 |
Why?
|
Brain | 20 | 2023 | 26385 | 0.890 |
Why?
|
Stem Cells | 12 | 2010 | 3567 | 0.850 |
Why?
|
Lymphoma, Non-Hodgkin | 5 | 2021 | 1381 | 0.830 |
Why?
|
Granuloma, Foreign-Body | 1 | 2021 | 45 | 0.770 |
Why?
|
Antineoplastic Agents | 17 | 2021 | 13695 | 0.750 |
Why?
|
Radiation Injuries, Experimental | 2 | 2017 | 91 | 0.740 |
Why?
|
Neoplasms | 9 | 2023 | 21683 | 0.720 |
Why?
|
Vidarabine | 1 | 2020 | 345 | 0.690 |
Why?
|
Immunotherapy | 8 | 2023 | 4445 | 0.660 |
Why?
|
Methotrexate | 2 | 2023 | 1727 | 0.640 |
Why?
|
Neoplasms, Neuroepithelial | 1 | 2018 | 45 | 0.640 |
Why?
|
Trigeminal Nerve Diseases | 1 | 2019 | 55 | 0.630 |
Why?
|
Spinal Cord Diseases | 1 | 2021 | 298 | 0.630 |
Why?
|
Leukoencephalopathies | 1 | 2020 | 238 | 0.620 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2020 | 340 | 0.590 |
Why?
|
Central Nervous System Diseases | 1 | 2021 | 518 | 0.590 |
Why?
|
Nervous System Diseases | 3 | 2021 | 1622 | 0.580 |
Why?
|
Angiogenesis Inhibitors | 7 | 2021 | 2038 | 0.570 |
Why?
|
Enteric Nervous System | 2 | 2016 | 189 | 0.540 |
Why?
|
Radiotherapy | 4 | 2019 | 1533 | 0.530 |
Why?
|
Isocitrate Dehydrogenase | 6 | 2021 | 871 | 0.530 |
Why?
|
Neoplasm Recurrence, Local | 16 | 2023 | 9239 | 0.530 |
Why?
|
Glutarates | 5 | 2021 | 236 | 0.510 |
Why?
|
Cognition Disorders | 5 | 2019 | 4043 | 0.510 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2016 | 140 | 0.510 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2017 | 648 | 0.500 |
Why?
|
Regeneration | 2 | 2017 | 1485 | 0.470 |
Why?
|
Cell Transplantation | 1 | 2016 | 477 | 0.470 |
Why?
|
Stem Cell Transplantation | 4 | 2016 | 1620 | 0.460 |
Why?
|
Humans | 112 | 2024 | 744343 | 0.440 |
Why?
|
Spinal Cord Neoplasms | 1 | 2015 | 281 | 0.420 |
Why?
|
Lymphoma, B-Cell | 2 | 2019 | 931 | 0.410 |
Why?
|
Muscle Weakness | 1 | 2015 | 413 | 0.410 |
Why?
|
Medulloblastoma | 1 | 2017 | 683 | 0.390 |
Why?
|
Neuroglia | 4 | 2015 | 927 | 0.390 |
Why?
|
Diagnostic Imaging | 2 | 2017 | 3507 | 0.380 |
Why?
|
Back Pain | 1 | 2015 | 545 | 0.380 |
Why?
|
Meningeal Carcinomatosis | 2 | 2021 | 65 | 0.370 |
Why?
|
Bone Marrow Cells | 1 | 2017 | 2513 | 0.350 |
Why?
|
Bone Marrow Transplantation | 1 | 2017 | 2765 | 0.350 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2023 | 11524 | 0.340 |
Why?
|
Magnetic Resonance Spectroscopy | 4 | 2021 | 3760 | 0.330 |
Why?
|
Neural Stem Cells | 1 | 2016 | 851 | 0.330 |
Why?
|
Antigens, CD19 | 3 | 2022 | 380 | 0.320 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2023 | 5442 | 0.320 |
Why?
|
Cell Lineage | 4 | 2010 | 2504 | 0.320 |
Why?
|
Combined Modality Therapy | 8 | 2023 | 8642 | 0.320 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2019 | 3508 | 0.300 |
Why?
|
Magnetic Resonance Imaging | 19 | 2024 | 35421 | 0.300 |
Why?
|
Brain Diseases | 3 | 2018 | 1563 | 0.300 |
Why?
|
Lateral Ventricles | 2 | 2021 | 146 | 0.300 |
Why?
|
Drug Evaluation | 1 | 2008 | 647 | 0.300 |
Why?
|
Necrosis | 3 | 2020 | 1643 | 0.290 |
Why?
|
Lower Extremity | 1 | 2015 | 1158 | 0.290 |
Why?
|
Hydrothorax | 1 | 2006 | 16 | 0.290 |
Why?
|
Meningeal Neoplasms | 3 | 2022 | 1241 | 0.280 |
Why?
|
Bone Marrow | 1 | 2016 | 2948 | 0.270 |
Why?
|
Multiple Myeloma | 1 | 2023 | 5181 | 0.260 |
Why?
|
Eukaryotic Initiation Factor-2B | 1 | 2005 | 9 | 0.260 |
Why?
|
Cerebral Hemorrhage | 1 | 2017 | 2647 | 0.260 |
Why?
|
T-Lymphocytes | 5 | 2023 | 10180 | 0.250 |
Why?
|
Adult | 39 | 2023 | 214055 | 0.250 |
Why?
|
Cell Culture Techniques | 2 | 2002 | 1678 | 0.250 |
Why?
|
Neurons | 6 | 2015 | 9338 | 0.240 |
Why?
|
Herpesvirus 6, Human | 1 | 2004 | 95 | 0.230 |
Why?
|
Fatal Outcome | 2 | 2020 | 1850 | 0.230 |
Why?
|
Retrospective Studies | 16 | 2024 | 77449 | 0.230 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2005 | 528 | 0.230 |
Why?
|
Male | 46 | 2022 | 350118 | 0.230 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2022 | 2540 | 0.230 |
Why?
|
Radiosurgery | 3 | 2023 | 1329 | 0.220 |
Why?
|
Therapies, Investigational | 1 | 2023 | 112 | 0.220 |
Why?
|
B-Cell Maturation Antigen | 1 | 2023 | 140 | 0.210 |
Why?
|
Astrocytes | 3 | 2005 | 1270 | 0.210 |
Why?
|
Mutation | 11 | 2024 | 29786 | 0.210 |
Why?
|
Oligodendroglia | 1 | 2006 | 517 | 0.210 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2023 | 284 | 0.210 |
Why?
|
DNA Modification Methylases | 2 | 2020 | 206 | 0.210 |
Why?
|
Chromosomes, Human, Pair 1 | 2 | 2021 | 658 | 0.210 |
Why?
|
Neoplastic Stem Cells | 1 | 2010 | 1376 | 0.210 |
Why?
|
Gangliosides | 1 | 2002 | 137 | 0.200 |
Why?
|
Cell Differentiation | 6 | 2009 | 11483 | 0.200 |
Why?
|
Transplantation, Autologous | 3 | 2023 | 2124 | 0.190 |
Why?
|
Epilepsy, Generalized | 1 | 2023 | 174 | 0.190 |
Why?
|
DNA Repair Enzymes | 2 | 2020 | 349 | 0.190 |
Why?
|
Inositol | 1 | 2021 | 218 | 0.190 |
Why?
|
Maximum Tolerated Dose | 2 | 2020 | 892 | 0.190 |
Why?
|
Quinolines | 2 | 2016 | 732 | 0.190 |
Why?
|
Middle Aged | 32 | 2022 | 213383 | 0.190 |
Why?
|
Peritoneal Neoplasms | 1 | 2006 | 665 | 0.180 |
Why?
|
Aged | 27 | 2023 | 163280 | 0.180 |
Why?
|
Meningioma | 2 | 2022 | 1209 | 0.180 |
Why?
|
Disease Management | 3 | 2020 | 2459 | 0.180 |
Why?
|
Female | 43 | 2022 | 380194 | 0.180 |
Why?
|
Photons | 1 | 2023 | 588 | 0.170 |
Why?
|
Prognosis | 12 | 2024 | 29063 | 0.170 |
Why?
|
Epilepsies, Partial | 1 | 2023 | 436 | 0.170 |
Why?
|
Protein Kinase Inhibitors | 4 | 2024 | 5535 | 0.170 |
Why?
|
Stuttering | 1 | 2018 | 25 | 0.170 |
Why?
|
Neurogenesis | 2 | 2016 | 838 | 0.160 |
Why?
|
Demyelinating Diseases | 2 | 2015 | 354 | 0.160 |
Why?
|
Disease Progression | 5 | 2022 | 13284 | 0.160 |
Why?
|
Signal Transduction | 2 | 2012 | 23403 | 0.160 |
Why?
|
Protons | 1 | 2023 | 1127 | 0.160 |
Why?
|
Intracranial Hemorrhages | 1 | 2003 | 855 | 0.150 |
Why?
|
Pyridazines | 1 | 2019 | 202 | 0.150 |
Why?
|
Radiotherapy Dosage | 2 | 2023 | 2879 | 0.150 |
Why?
|
Head | 1 | 2023 | 880 | 0.150 |
Why?
|
Neurosurgical Procedures | 1 | 2009 | 2002 | 0.150 |
Why?
|
Young Adult | 10 | 2021 | 56430 | 0.150 |
Why?
|
Testicular Neoplasms | 1 | 2003 | 804 | 0.150 |
Why?
|
Cholinesterase Inhibitors | 1 | 2019 | 238 | 0.150 |
Why?
|
Lung Neoplasms | 4 | 2024 | 13102 | 0.150 |
Why?
|
Animals | 16 | 2023 | 168757 | 0.140 |
Why?
|
Folic Acid | 1 | 2023 | 1300 | 0.140 |
Why?
|
Evidence-Based Practice | 1 | 2020 | 500 | 0.140 |
Why?
|
Lactams, Macrocyclic | 1 | 2017 | 320 | 0.130 |
Why?
|
Capillary Permeability | 1 | 2019 | 798 | 0.130 |
Why?
|
Neurodegenerative Diseases | 1 | 2005 | 1061 | 0.130 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 705 | 0.130 |
Why?
|
Antineoplastic Protocols | 1 | 2015 | 50 | 0.130 |
Why?
|
Serotonin 5-HT4 Receptor Agonists | 1 | 2015 | 11 | 0.130 |
Why?
|
Forecasting | 2 | 2019 | 2951 | 0.130 |
Why?
|
Diagnosis, Differential | 3 | 2019 | 12959 | 0.130 |
Why?
|
Karnofsky Performance Status | 4 | 2019 | 173 | 0.130 |
Why?
|
Corpus Callosum | 2 | 2014 | 737 | 0.130 |
Why?
|
Optic Nerve Neoplasms | 1 | 2015 | 44 | 0.130 |
Why?
|
Dexamethasone | 1 | 2022 | 1951 | 0.130 |
Why?
|
Melanoma | 2 | 2023 | 5510 | 0.130 |
Why?
|
Methylphenidate | 1 | 2019 | 473 | 0.120 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2019 | 571 | 0.120 |
Why?
|
Receptor Protein-Tyrosine Kinases | 3 | 2017 | 1660 | 0.120 |
Why?
|
Cerebral Ventricle Neoplasms | 1 | 2014 | 44 | 0.120 |
Why?
|
Erythropoietin | 1 | 2019 | 726 | 0.120 |
Why?
|
Drug Delivery Systems | 1 | 2006 | 2219 | 0.120 |
Why?
|
Treatment Outcome | 12 | 2020 | 63114 | 0.120 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2004 | 2942 | 0.120 |
Why?
|
Survival Rate | 6 | 2021 | 12788 | 0.120 |
Why?
|
Practice Guidelines as Topic | 2 | 2021 | 7279 | 0.120 |
Why?
|
Phenylurea Compounds | 1 | 2016 | 528 | 0.110 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2016 | 664 | 0.110 |
Why?
|
Valproic Acid | 1 | 2016 | 445 | 0.110 |
Why?
|
Imidazoles | 1 | 2019 | 1206 | 0.110 |
Why?
|
Aged, 80 and over | 8 | 2020 | 57776 | 0.110 |
Why?
|
Longitudinal Studies | 3 | 2021 | 13989 | 0.110 |
Why?
|
Tumor Suppressor Proteins | 2 | 2020 | 2849 | 0.110 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 5221 | 0.100 |
Why?
|
Gene Rearrangement | 1 | 2017 | 1179 | 0.100 |
Why?
|
Stereotaxic Techniques | 1 | 2014 | 536 | 0.100 |
Why?
|
Cells, Cultured | 4 | 2016 | 19229 | 0.100 |
Why?
|
C-Reactive Protein | 1 | 2023 | 3778 | 0.100 |
Why?
|
src-Family Kinases | 1 | 2014 | 551 | 0.100 |
Why?
|
Child | 6 | 2023 | 77709 | 0.100 |
Why?
|
Colitis | 2 | 2021 | 1170 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2020 | 1580 | 0.100 |
Why?
|
Imaging, Three-Dimensional | 3 | 2020 | 4042 | 0.100 |
Why?
|
Electroencephalography | 4 | 2023 | 6150 | 0.100 |
Why?
|
Laser Therapy | 1 | 2018 | 1072 | 0.100 |
Why?
|
Cell Division | 3 | 2004 | 4568 | 0.100 |
Why?
|
Mice | 6 | 2023 | 81183 | 0.100 |
Why?
|
Macrophages | 2 | 2017 | 5655 | 0.100 |
Why?
|
Hematologic Neoplasms | 1 | 2022 | 1832 | 0.090 |
Why?
|
Tumor Microenvironment | 3 | 2023 | 3586 | 0.090 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2002 | 3617 | 0.090 |
Why?
|
Thoracic Vertebrae | 1 | 2015 | 608 | 0.090 |
Why?
|
Central Nervous System Stimulants | 1 | 2019 | 1148 | 0.090 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 1519 | 0.090 |
Why?
|
Aniline Compounds | 1 | 2014 | 986 | 0.090 |
Why?
|
Medical Oncology | 1 | 2021 | 2265 | 0.090 |
Why?
|
Anti-Retroviral Agents | 1 | 2019 | 1715 | 0.090 |
Why?
|
Nitriles | 1 | 2014 | 956 | 0.090 |
Why?
|
Promoter Regions, Genetic | 1 | 2020 | 5867 | 0.080 |
Why?
|
Neoplasm Proteins | 1 | 2021 | 3703 | 0.080 |
Why?
|
Adenocarcinoma | 1 | 2006 | 6364 | 0.080 |
Why?
|
Genotype | 1 | 2023 | 12951 | 0.080 |
Why?
|
Cervical Vertebrae | 1 | 2015 | 975 | 0.080 |
Why?
|
Genetic Variation | 1 | 2004 | 6544 | 0.080 |
Why?
|
Frontal Lobe | 1 | 2015 | 1406 | 0.080 |
Why?
|
Enzyme Inhibitors | 2 | 2018 | 3798 | 0.080 |
Why?
|
Autoimmune Diseases | 1 | 2020 | 2133 | 0.080 |
Why?
|
Indoles | 2 | 2014 | 1839 | 0.080 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2017 | 2455 | 0.080 |
Why?
|
Monocytes | 1 | 2017 | 2596 | 0.080 |
Why?
|
Brain Damage, Chronic | 1 | 2009 | 265 | 0.080 |
Why?
|
Bromodeoxyuridine | 2 | 2008 | 322 | 0.080 |
Why?
|
Cell Proliferation | 3 | 2016 | 10481 | 0.080 |
Why?
|
Nausea | 2 | 2021 | 673 | 0.080 |
Why?
|
Transplantation Conditioning | 1 | 2014 | 1598 | 0.080 |
Why?
|
Epilepsy | 1 | 2023 | 3310 | 0.070 |
Why?
|
Echoencephalography | 1 | 2007 | 135 | 0.070 |
Why?
|
Fibrinolytic Agents | 1 | 2017 | 2158 | 0.070 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 2214 | 0.070 |
Why?
|
DNA Methylation | 1 | 2020 | 4286 | 0.070 |
Why?
|
Ultrasonography, Doppler, Color | 1 | 2007 | 233 | 0.070 |
Why?
|
Follow-Up Studies | 6 | 2021 | 39050 | 0.070 |
Why?
|
Adolescent | 7 | 2021 | 85781 | 0.070 |
Why?
|
Disease-Free Survival | 4 | 2020 | 6895 | 0.070 |
Why?
|
Doxorubicin | 2 | 2004 | 2234 | 0.070 |
Why?
|
Drug Administration Schedule | 4 | 2018 | 4933 | 0.070 |
Why?
|
Cell Survival | 1 | 2016 | 5882 | 0.070 |
Why?
|
Lumbar Vertebrae | 1 | 2015 | 1848 | 0.070 |
Why?
|
Mice, Inbred CBA | 1 | 2006 | 448 | 0.060 |
Why?
|
Proto-Oncogene Proteins | 1 | 2017 | 4554 | 0.060 |
Why?
|
Child, Preschool | 2 | 2018 | 41006 | 0.060 |
Why?
|
Diffusion Tensor Imaging | 1 | 2015 | 2305 | 0.060 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2020 | 8428 | 0.060 |
Why?
|
Cytopathogenic Effect, Viral | 1 | 2004 | 156 | 0.060 |
Why?
|
Survival Analysis | 5 | 2021 | 10252 | 0.060 |
Why?
|
Amino Acid Transport System X-AG | 1 | 2004 | 40 | 0.060 |
Why?
|
Myelin Sheath | 1 | 2008 | 652 | 0.060 |
Why?
|
Brain Injuries | 1 | 2016 | 2025 | 0.060 |
Why?
|
Rats | 4 | 2009 | 24260 | 0.060 |
Why?
|
Ifosfamide | 1 | 2003 | 228 | 0.060 |
Why?
|
Disease Models, Animal | 2 | 2017 | 18029 | 0.060 |
Why?
|
Ovarian Neoplasms | 1 | 2020 | 4838 | 0.060 |
Why?
|
Fluorouracil | 1 | 2008 | 1619 | 0.060 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2004 | 424 | 0.060 |
Why?
|
Liver Neoplasms | 1 | 2019 | 4253 | 0.060 |
Why?
|
Germinoma | 1 | 2003 | 133 | 0.060 |
Why?
|
S Phase | 1 | 2004 | 423 | 0.050 |
Why?
|
Neurotrophin 3 | 1 | 2002 | 59 | 0.050 |
Why?
|
G1 Phase | 1 | 2004 | 415 | 0.050 |
Why?
|
Neural Cell Adhesion Molecule L1 | 1 | 2002 | 40 | 0.050 |
Why?
|
Sialic Acids | 1 | 2002 | 127 | 0.050 |
Why?
|
Mice, Knockout | 1 | 2017 | 14557 | 0.050 |
Why?
|
Carbamazepine | 1 | 2023 | 229 | 0.050 |
Why?
|
Oligodendroglioma | 1 | 2004 | 279 | 0.050 |
Why?
|
Etoposide | 1 | 2003 | 641 | 0.050 |
Why?
|
Oxygen | 1 | 2013 | 4189 | 0.050 |
Why?
|
Brain Tissue Transplantation | 1 | 2002 | 81 | 0.050 |
Why?
|
Seizures | 2 | 2023 | 2859 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2020 | 6538 | 0.050 |
Why?
|
Immunosuppressive Agents | 1 | 2014 | 4149 | 0.050 |
Why?
|
Image Interpretation, Computer-Assisted | 2 | 2020 | 3327 | 0.050 |
Why?
|
Antigens, Differentiation | 1 | 2004 | 927 | 0.050 |
Why?
|
Anorexia | 1 | 2021 | 161 | 0.050 |
Why?
|
Patient Advocacy | 1 | 2023 | 353 | 0.050 |
Why?
|
Mice, Inbred C57BL | 2 | 2016 | 21827 | 0.050 |
Why?
|
Prospective Studies | 6 | 2022 | 53288 | 0.050 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2002 | 599 | 0.050 |
Why?
|
Risk Assessment | 2 | 2019 | 23338 | 0.050 |
Why?
|
Carotid Stenosis | 1 | 2007 | 854 | 0.050 |
Why?
|
Electronics | 1 | 2021 | 322 | 0.050 |
Why?
|
Cerebrospinal Fluid Proteins | 1 | 2020 | 69 | 0.040 |
Why?
|
Anticonvulsants | 2 | 2023 | 1916 | 0.040 |
Why?
|
Biological Products | 2 | 2019 | 860 | 0.040 |
Why?
|
Ki-67 Antigen | 1 | 2022 | 644 | 0.040 |
Why?
|
Procarbazine | 1 | 2019 | 181 | 0.040 |
Why?
|
Lomustine | 1 | 2019 | 59 | 0.040 |
Why?
|
Prevalence | 1 | 2017 | 15226 | 0.040 |
Why?
|
Hepatitis | 1 | 2021 | 227 | 0.040 |
Why?
|
Tretinoin | 1 | 2002 | 517 | 0.040 |
Why?
|
Cohort Studies | 3 | 2019 | 40561 | 0.040 |
Why?
|
Radionuclide Imaging | 1 | 2003 | 2031 | 0.040 |
Why?
|
Chemotherapy, Cancer, Regional Perfusion | 1 | 2019 | 85 | 0.040 |
Why?
|
Mood Disorders | 1 | 2006 | 1106 | 0.040 |
Why?
|
Receptor, TIE-2 | 1 | 2019 | 178 | 0.040 |
Why?
|
Cell Death | 1 | 2004 | 1706 | 0.040 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2019 | 367 | 0.040 |
Why?
|
Fetus | 2 | 2004 | 1880 | 0.040 |
Why?
|
Survivors | 1 | 2009 | 2291 | 0.040 |
Why?
|
Glutamic Acid | 1 | 2004 | 1169 | 0.040 |
Why?
|
Dura Mater | 1 | 2020 | 291 | 0.040 |
Why?
|
Biological Evolution | 1 | 2004 | 1076 | 0.040 |
Why?
|
Tumor Burden | 1 | 2023 | 1915 | 0.040 |
Why?
|
Cisplatin | 1 | 2003 | 1662 | 0.040 |
Why?
|
Vincristine | 1 | 2019 | 1039 | 0.040 |
Why?
|
Rats, Sprague-Dawley | 2 | 2006 | 8301 | 0.040 |
Why?
|
Synaptic Transmission | 1 | 2004 | 1178 | 0.040 |
Why?
|
Pattern Recognition, Automated | 1 | 2023 | 1005 | 0.040 |
Why?
|
Salvage Therapy | 1 | 2003 | 1275 | 0.040 |
Why?
|
Vomiting | 1 | 2020 | 636 | 0.040 |
Why?
|
Lactams | 1 | 2017 | 156 | 0.040 |
Why?
|
Exanthema | 1 | 2021 | 501 | 0.040 |
Why?
|
Ischemia | 1 | 2006 | 1907 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2019 | 546 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2020 | 10943 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2019 | 552 | 0.030 |
Why?
|
Hippocampus | 1 | 2008 | 3675 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2018 | 15295 | 0.030 |
Why?
|
World Health Organization | 1 | 2021 | 1318 | 0.030 |
Why?
|
Treatment Failure | 1 | 2021 | 2618 | 0.030 |
Why?
|
Deoxyuridine | 1 | 2015 | 33 | 0.030 |
Why?
|
Integrin alpha2 | 1 | 2015 | 40 | 0.030 |
Why?
|
Water | 1 | 2021 | 1395 | 0.030 |
Why?
|
Ablation Techniques | 1 | 2018 | 249 | 0.030 |
Why?
|
Immunohistochemistry | 3 | 2004 | 11366 | 0.030 |
Why?
|
Thiotepa | 1 | 2014 | 66 | 0.030 |
Why?
|
Time Factors | 1 | 2017 | 40075 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2023 | 12354 | 0.030 |
Why?
|
Point Mutation | 1 | 2000 | 1623 | 0.030 |
Why?
|
Chromosome Deletion | 1 | 2019 | 1401 | 0.030 |
Why?
|
Dextran Sulfate | 1 | 2015 | 236 | 0.030 |
Why?
|
Gene Dosage | 1 | 2019 | 1252 | 0.030 |
Why?
|
Fatigue | 1 | 2021 | 1531 | 0.030 |
Why?
|
Cell Transdifferentiation | 1 | 2015 | 172 | 0.030 |
Why?
|
Fever | 1 | 2021 | 1616 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2020 | 1405 | 0.030 |
Why?
|
Up-Regulation | 2 | 2019 | 4217 | 0.030 |
Why?
|
Aminopyridines | 1 | 2017 | 542 | 0.030 |
Why?
|
Busulfan | 1 | 2014 | 263 | 0.030 |
Why?
|
Base Sequence | 1 | 2005 | 12797 | 0.030 |
Why?
|
SOXB1 Transcription Factors | 1 | 2015 | 284 | 0.030 |
Why?
|
Quality of Life | 4 | 2023 | 12804 | 0.030 |
Why?
|
Chick Embryo | 1 | 2015 | 982 | 0.030 |
Why?
|
HIV Infections | 1 | 2019 | 16718 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2023 | 8949 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2008 | 16689 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2023 | 2916 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2020 | 20822 | 0.030 |
Why?
|
Cytarabine | 1 | 2014 | 692 | 0.030 |
Why?
|
Consensus | 1 | 2021 | 2959 | 0.030 |
Why?
|
Internationality | 1 | 2017 | 1003 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2018 | 956 | 0.030 |
Why?
|
Molecular Sequence Data | 1 | 2005 | 18111 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2020 | 2480 | 0.020 |
Why?
|
Hyperglycemia | 1 | 2020 | 1373 | 0.020 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 693 | 0.020 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2019 | 1873 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2023 | 3479 | 0.020 |
Why?
|
Caregivers | 1 | 2022 | 2094 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2020 | 14722 | 0.020 |
Why?
|
NF-kappa B | 1 | 2019 | 2499 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2013 | 1799 | 0.020 |
Why?
|
Patient Care Team | 1 | 2021 | 2531 | 0.020 |
Why?
|
Autopsy | 1 | 2013 | 1020 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2020 | 4851 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2014 | 2274 | 0.020 |
Why?
|
Administration, Oral | 1 | 2016 | 3913 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 2014 | 2242 | 0.020 |
Why?
|
Tetrazolium Salts | 1 | 2008 | 96 | 0.020 |
Why?
|
Models, Statistical | 1 | 2023 | 5102 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2013 | 2886 | 0.020 |
Why?
|
Logistic Models | 1 | 2022 | 13408 | 0.020 |
Why?
|
Anxiety | 1 | 2022 | 4297 | 0.020 |
Why?
|
Pyrazoles | 1 | 2017 | 1972 | 0.020 |
Why?
|
Quinazolines | 1 | 2013 | 1356 | 0.020 |
Why?
|
In Situ Nick-End Labeling | 1 | 2008 | 643 | 0.020 |
Why?
|
Colon | 1 | 2015 | 1772 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2022 | 4245 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 3870 | 0.020 |
Why?
|
Neoplasm Staging | 2 | 2015 | 11031 | 0.020 |
Why?
|
Neovascularization, Pathologic | 1 | 2016 | 2635 | 0.020 |
Why?
|
Auditory Pathways | 1 | 2008 | 233 | 0.020 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2008 | 712 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15076 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2016 | 6489 | 0.020 |
Why?
|
Sulfonamides | 1 | 2015 | 1938 | 0.020 |
Why?
|
Patient Selection | 1 | 2017 | 4215 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9274 | 0.020 |
Why?
|
Gene Expression | 1 | 2018 | 7799 | 0.020 |
Why?
|
Phenotype | 1 | 2002 | 16365 | 0.020 |
Why?
|
Excitatory Amino Acid Transporter 4 | 1 | 2004 | 4 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2019 | 5172 | 0.020 |
Why?
|
Glutamate Plasma Membrane Transport Proteins | 1 | 2004 | 11 | 0.020 |
Why?
|
Cytokines | 1 | 2019 | 7322 | 0.020 |
Why?
|
Excitatory Amino Acid Transporter 1 | 1 | 2004 | 19 | 0.020 |
Why?
|
Excitatory Amino Acid Transporter 3 | 1 | 2004 | 32 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2013 | 6171 | 0.010 |
Why?
|
Cerebral Cortex | 1 | 2000 | 5708 | 0.010 |
Why?
|
Bone Morphogenetic Protein 4 | 1 | 2004 | 162 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2019 | 6234 | 0.010 |
Why?
|
Excitatory Amino Acid Transporter 2 | 1 | 2004 | 77 | 0.010 |
Why?
|
Inflammation | 1 | 2023 | 10638 | 0.010 |
Why?
|
Algorithms | 1 | 2023 | 13881 | 0.010 |
Why?
|
Infant | 1 | 2005 | 35136 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 9959 | 0.010 |
Why?
|
Antigens, CD | 1 | 2013 | 4026 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2013 | 5974 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2015 | 9734 | 0.010 |
Why?
|
Depression | 1 | 2022 | 7766 | 0.010 |
Why?
|
Massachusetts | 1 | 2014 | 8663 | 0.010 |
Why?
|
DNA, Antisense | 1 | 2000 | 46 | 0.010 |
Why?
|
Symporters | 1 | 2004 | 362 | 0.010 |
Why?
|
Thiazoles | 1 | 2008 | 1483 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2008 | 2699 | 0.010 |
Why?
|
Epilepsy, Tonic-Clonic | 1 | 2000 | 49 | 0.010 |
Why?
|
Action Potentials | 1 | 2008 | 1806 | 0.010 |
Why?
|
Drug Carriers | 1 | 2004 | 693 | 0.010 |
Why?
|
Tamoxifen | 1 | 2004 | 981 | 0.010 |
Why?
|
Protein Isoforms | 1 | 2004 | 1730 | 0.010 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2004 | 1107 | 0.010 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2004 | 838 | 0.010 |
Why?
|
Polyethylene Glycols | 1 | 2004 | 1182 | 0.010 |
Why?
|
Animals, Newborn | 1 | 2004 | 2726 | 0.010 |
Why?
|
Germany | 1 | 2000 | 862 | 0.010 |
Why?
|
Liposomes | 1 | 2001 | 759 | 0.010 |
Why?
|
X Chromosome | 1 | 2000 | 814 | 0.010 |
Why?
|
Remission Induction | 1 | 2001 | 2386 | 0.010 |
Why?
|
DNA Primers | 1 | 2000 | 2892 | 0.010 |
Why?
|
Syndrome | 1 | 2000 | 3251 | 0.010 |
Why?
|
Reoperation | 1 | 2003 | 4201 | 0.010 |
Why?
|
Pedigree | 1 | 2000 | 4644 | 0.010 |
Why?
|
Peptides | 1 | 2004 | 4409 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2007 | 19905 | 0.010 |
Why?
|
Cell Line | 1 | 2004 | 15997 | 0.010 |
Why?
|
Models, Biological | 1 | 2004 | 9583 | 0.000 |
Why?
|